Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.65 |
| ▸ | CYSLTR1 | Q9Y271 | 6/20 | 0.64 |
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 0.64 |
| ▸ | PPARG | P37231 | 7/20 | 0.64 |
| ▸ | PPARD | Q03181 | 5/20 | 0.64 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.64 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.61 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7067424 | 0.83 | GPBAR1 (0.47) | CYSLTR1CYSLTR2FFAR1AKR1B1ALOX5 | |
| SCHEMBL7070000 | 0.83 | PPARA (0.58) | PPARAPPARGPPARD | |
| SCHEMBL16415847 | 0.82 | PPARA (0.70) | PPARAPPARGPPARD | |
| SCHEMBL7069937 | 0.82 | PPARA (0.67) | PPARAPPARGPPARD | |
| SCHEMBL7070013 | 0.82 | PPARA (0.67) | PPARAPPARGPPARD | |
| SCHEMBL6494550 | 0.81 | PPARA (0.70) | PPARAPPARGPPARD | |
| SCHEMBL6494556 | 0.81 | PPARA (0.70) | PPARAPPARGPPARD | |
| SCHEMBL6494552 | 0.81 | PPARA (0.70) | PPARAPPARGPPARD | |
| SCHEMBL16415813 | 0.81 | PPARA (0.92) | PPARAPPARGPPARD | |
| SCHEMBL5608022 | 0.81 | PPARA (0.92) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | MITSUI CHEMICALS, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | PPARG, PPARD, PPARA | PPARA 3/4885CYSLTR1 2748/4885CYSLTR2 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.